Having regard to the provisions of the PRAC Report on the Periodic Safety Update Reports (PSURs) for glimepiride/pioglitazone hydrochloride, metformin/pioglitazone, pioglitazone, the scientific conclusions of the CHMP are as follows:
The TAC provided updated information related to important identified risks and important potential risks, as listed in the summary of safety problems. The data presented during the current reporting period did not provide new information that would allow further reduction, mitigation or characterisation of these risks. According to the data presented, the risk minimisation measures approved in the product information are considered adequate for the safety problems listed.
Given the accumulation of data since the implementation of additional risk minimisation measures, the PRAC accepted the TAC's proposal to remove the additional risk minimisation measures. As a consequence, the conditions or restrictions related to the safe and effective use of the medicine should be updated to remove the additional risk minimisation measures. The PGR has been updated accordingly.
The CHMP agrees with the scientific conclusions of the PRAC.
Reasons for the modification of the conditions of the Marketing Authorisation(s)
According to the scientific conclusions for glimepiride/pioglitazone hydrochloride, metformin/pioglitazone, pioglitazone, the CHMP considers that the benefit-risk balance of the medicine or medicines containing glimepiride/pioglitazone hydrochloride, metformin/pioglitazone, pioglitazone is not modified subject to the proposed changes in the product information.
The CHMP recommends that the conditions of the Marketing Authorisation(s) be modified.
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.